Best Diversified Pharmaceuticals Companies in California, United States
The 133 best Diversified Pharmaceuticals companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Gilead.
Ranked: Best Diversified Pharmaceuticals companies in California
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | $2.6B | 16 mo ago | 4,267 | 1987 | — | — | — |
| 2 | Inhibrx Antibody-based immunotherapeutics for cancer and infectious diseases 45Funding top 25%Patents top 29%Product top 32%Innovation top 33% All 11 signals ▾Fundingtop 25% Patentstop 29% Producttop 32% Innovationtop 33% Techtop 42% Moatbottom 49% Growthbottom 43% Marketbottom 41% Globalbottom 40% Newsbottom 32% Fin. healthbottom 31% Funding: Raised $469M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Patents: 499 patents matched (strict assignee match) · 161 filings since 2022 vs 269 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $469M | 15 mo ago | 112 112 → 111 (-1%) | 2009 | — | 499 patents Engineering multispecific therapeutic proteins (antibodies, DR5, serpin fusions) for immune modulation | 1 launch |
| 3 | Arrowhead Pharmaceuticals Developer of therapeutics to treat multiple diseases | $290M | 12 mo ago | 427 427 → 809 (+89%) | 1989 | Christopher Anzalone CEO & President | 1,202 patents RNA interference therapeutics targeting disease genes and targeted delivery systems | — |
| 4 | Pearl Therapeutics Respiratory disease research | $232M | 158 mo ago | 134 | 2006 | Pascal Soriot CEO | 304 patents Inhalable drug delivery formulations and devices for multi‑agent respiratory therapies. | — |
| 5 | FibroGen Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible… | $215M | 138 mo ago | 592 | 1993 | Thane Wettig Chief Executive Officer | 748 patents Therapeutics targeting HIF prolyl hydroxylase inhibition and immuno‑modulatory antibodies (galectin‑9, CCR8). | — |
| 6 | Sagimet Biosciences Developer of inhibitor-based drugs for treating cancer and dysfunctional metabolic diseases | $209M | 65 mo ago | 10 | 2007 | Dave Happel President & CEO | 46 patents Therapeutic modulation of fatty acid synthesis for metabolic liver disease | — |
| 7 | Amgen Developer of pharmaceutical products for treating multiple diseases | $175M | 171 mo ago | 26,700 26,700 → 40,935 (+53%) | 1980 | Robert Bradway CEO & Chairman | 20,433 patents Recombinant protein/peptide production, expression vectors, and purification of biologic therapeutics | — |
| 8 | Arena Pharmaceuticals Premier biopharmaceutical company dedicated to innovative medicines and healthcare solutions | $169M | 173 mo ago | 257 | 1997 | — | — | — |
| 9 | Armo BioSciences Immune modulatory biologic therapeutics for cancer, Atherosclerosis, fibrosis and inflammatory bowel disease | $167M | 96 mo ago | 21 | 2012 | — | 158 patents Therapeutic IL-10 biologics for immunomodulation and cancer immunotherapy | — |
| 10 | Catalyst Biosciences Protease therapies for hemophilia, renal delayed graft function (DGF) & age-related macular degeneration (AMD) | $165M | 131 mo ago | 45 | 1997 | Han Ying CEO | 299 patents Therapeutic proteins and formulations targeting complement serine proteases and related pathways | — |
| 11 | Nurix Therapeutics Platform for drug development for controlling natural proteins | $145M | 74 mo ago | 284 284 → 368 (+30%) | 2009 | John Kuriyan Co-Founder | 259 patents Targeted protein degradation (PROTAC) of disease-relevant kinases and immune regulators | 2 partnerships |
| 12 | Cullgen Biopharmaceutical company pioneering targeted protein degradation for innovative medicines | $121M | 37 mo ago | 5 | 2018 | Yue Xiong Co-Founder | 4 patents Small‑molecule oncology drugs and targeted protein degraders for cancer therapy | — |
| 13 | Cellular Biomedicine Group Cellular therapeutics for cancer, orthopaedic disorders, and COPD | $120M | 56 mo ago | 217 | 2001 | — | 51 patents CAR-T cell immunotherapies targeting CD19/CD20 and related immune cell manufacturing | — |
| 14 | LP Pharmaceuticals Developer of novel pharmaceutical products and advanced drug delivery systems | $102M | 70 mo ago | 304 | 2012 | — | 437 patents Patents concentrated in health & consumer products | — |
| 15 | ZS Pharma Develop ion-trap therapies for the treatment of hyperkalemia | $92M | 143 mo ago | 200 | 2008 | — | 248 patents Oral zirconium silicate potassium binders for treating hyperkalemia | — |
| 16 | AnaptysBio Developer of immunology therapeutics for cancer and inflammatory diseases | $86M | 131 mo ago | 101 101 → 74 (-27%) | 2005 | — | 326 patents Therapeutic antibodies/modulators targeting immune checkpoints and cytokine receptors for inflammation | — |
| 17 | TargeGen Small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis)… | $74M | 201 mo ago | 5 | 2002 | Peter Herstall Ulrich Founder & CEO | 173 patents Small-molecule kinase inhibitors for treating myelofibrosis and other hematologic diseases | — |
| 18 | Genentech R&D company focused on manufacturing drugs for multiple therapeutic areas | $72M | 16 mo ago | 13,500 | 1976 | Ashley Magargee Chief Executive Officer | 25,578 patents Therapeutic antibodies, cancer diagnostics, and small‑molecule drug synthesis in biotech | — |
| 19 | KAI Pharmaceuticals Drug discovery and development for treating secondary hyperparathyroidism | $63M | 241 mo ago | — | 2002 | Daria Mochly-Rosen Founder | 199 patents Peptide-based therapeutics targeting parathyroid hormone and phosphate regulation | — |
| 20 | Mast Therapeutics Develops therapies for serious or life-threatening diseases using MAST technology | $63M | 117 mo ago | 38 | 1995 | — | — | — |
| 21 | Bird Rock Bio Antibody therapeutics to G-Protein Coupled Receptors targets validated with small molecules | $63M | 113 mo ago | 14 | 2008 | — | — | — |
| 22 | Protego Biopharma Company developing novel therapeutics based on human genetic links | $52M | 56 mo ago | 24 | 2017 | — | 39 patents Small-molecule IRE1/XBP1 activators and diagnostics for light-chain amyloidosis | 1 job opening |
| 23 | Emerald Health Pharma Speciality company developing proprietary cannabinoid-derived medicines | $52M | 62 mo ago | 21 | 2017 | — | — | — |
| 24 | Appia Bio Developer of cell therapies | $52M | 61 mo ago | 39 | 2020 | JeenJoo Kang CEO | — | — |
| 25 | Allegro Ophthalmics Innovating ocular disease treatments by regulating integrin function and mitochondrial dysfunction | $48M | 76 mo ago | 5 | 2009 | — | 8 patents Formulations for treating dry eye syndrome using ocular surface lubricating agents. | — |
| 26 | Plexxikon Personalized medicine innovator, now closed, refer to Daiichi Sankyo | $46M | 264 mo ago | 65 | 2000 | — | 1,127 patents Design of heterocyclic small‑molecule inhibitors for kinases, IDO/TDO, and CD73 immunotherapy | — |
| 27 | OrphoMed Dimer conjugates gastrointestinal disorders, pain and diseases featuring amyloids. | $42M | 108 mo ago | 8 | 2014 | — | 75 patents Dimeric pharmaceutical compounds for analgesia, antipyresis, GI disorders, and cystic fibrosis | — |
| 28 | Solstice Biologics Providing solutions for targeting and delivering nucleic acid therapeutics | $40M | 126 mo ago | 4,443 | 2012 | — | 9 patents Modified oligonucleotide synthesis using chiral phosphoramidite auxiliaries for therapeutic nucleic acids | — |
| 29 | Nitrase Therapeutics R&D company manufacturing drugs for multiple therapeutic areas | $38M | 74 mo ago | 26 | 2018 | Irene Prenner Founder & CSO | — | — |
| 30 | Patara Pharma Immunomodulators (mast cell stabilizers) for allergic & inflammatory diseases. | $34M | 116 mo ago | — | 2013 | William Gerhart CEO and Founder | — | — |
| 31 | Altheos R&D company focused on manufacturing drugs for multiple therapeutic areas | $32M | 171 mo ago | — | 2010 | Henry H. Hsu CEO | — | — |
| 32 | Sorriso Pharmaceuticals R&D company focused on manufacturing disease-modifying antibodies for multiple therapeutics areas | $31M | 53 mo ago | 8 | 2020 | Ciara Kennedy President & Chief Executive Officer | — | — |
| 33 | Turn Biotechnologies Developer of cell based aging reversal therapies | $30M | 33 mo ago | 34 | 2018 | Marco Quarta Co-Founder & CSO | 37 patents Patents concentrated in chemistry & materials | — |
| 34 | Retrophin Drugs for the treatment of debilitating and often life-threatening diseases . | $29M | 152 mo ago | 380 | 2011 | Eric Dube CEO | 90 patents Small-molecule therapeutics for rare kidney and collagen disorders, plus vitamin B5 analog formulations | — |
| 35 | Virobay Anti-viral drug discovery and development based on protease inhibitor | $26M | 143 mo ago | 6 | 2006 | — | 153 patents Cysteine protease inhibitor drugs targeting HCV and cathepsin B for antiviral and neuroprotection | — |
| 36 | Fountain Therapeutics Developing first-in-class therapies for aging-related diseases and conditions | $26M | 55 mo ago | 17 | 2018 | Tom Cheung Co-Founder | — | — |
| 37 | Cellibre Producer of cellular agricultural products | $25M | 14 mo ago | 26 | 2017 | — | 35 patents Microbial cell engineering and enzymatic biosynthesis of cannabinoids and bakuchiol. | — |
| 38 | Sophiris Bio Develop engineered proteins to treat urological diseases and prostate cancer | $23M | 81 mo ago | 6 | 2003 | — | — | — |
| 39 | TesoRx Pharma Developing novel oral drug delivery platform for unmet medical needs | $23M | 86 mo ago | 4 | 2010 | — | — | — |
| 40 | International Stem Cell Corp. Regenerative medicine for ophthalmology, neurology and liver disease | $22M | 123 mo ago | 29 | 2001 | William Adams Co-Founder | — | — |
| 41 | Verseon Physics and AI-driven precision engineering of novel disease treatments | $19M | 85 mo ago | 60 | 2002 | Eniko Fodor Co-Founder & COO | 161 patents Small-molecule serine protease (thrombin) inhibitors for therapeutic pharmaceutical applications. | — |
| 42 | AgeX Therapeutics Regenerative medicine therapeutics for Aging related diseases | $16M | 87 mo ago | 9 | 2007 | — | — | — |
| 43 | Pin Therapeutics Developer of small molecule based therapeutics for the treatment of several diseases | $15M | 17 mo ago | 14 | 2017 | Hyunsun Jo Co-Founder & CEO | — | — |
| 44 | Synchronicity Pharma Developing circadian clock gene modulating therapeutics for treating multiple diseases | $15M | 79 mo ago | 12 | 2008 | — | — | — |
| 45 | Orphagen Pioneering small molecule therapies for cancer and inflammatory bowel disease | $12M | 18 mo ago | 7 | 2001 | — | — | — |
| 46 | Revel Pharmaceuticals Diversified pharmaceutical company | $10M | 23 mo ago | 5 | 2019 | David Spiegel Co-Founder | — | — |
| 47 | Artery Therapeutics Developing peptide therapeutics for neurodegenerative diseases and cardiovascular disease | $9M | 13 mo ago | — | 2004 | Jan Johansson President & CEO | — | — |
| 48 | Mandalmed Developing therapies for fibrosis by modulating glycobiology and innate immunity | $6M | 22 mo ago | 5 | 2000 | Constance John Founder & CEO | 14 patents Patents concentrated in health & consumer products | — |
| 49 | Intolerant Antibodies Diversified pharmaceuticals offering medicines for consumers | $1M | 25 mo ago | — | 2024 | — | — | — |
| 50 | Oak Therapeutics Innovative oral dissolvable strips for improved medication delivery and patient adherence | $475K | 33 mo ago | — | 2014 | — | — | — |
Top 12 Diversified Pharmaceuticals companies in California
#1
Acquired · Foster City, California · founded 1987 · 4267 employees$2.6Braised▾
Gilead is a developer of medicines to treat HIV/AIDS, liver diseases, cancer & others. It is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. It has developed many medicines such as Lenacapavir capsid inhibitor (GS-6207) for HIV, Long-acting treatment: 2 bNAbs (GS-5423, GS-2872), Selgantolimod TLR-8 agonist (GS-9688), PD-L1 inhibitor (GS-4224) HBV cure, and many more. In 2022, the company recorded annual revenues of $27.28B and a net profit of $4.59B.
- Jan 2025Post IPO$290K
- Jul 2020Grant (prize money)$82M
- Jan 2020Grant (prize money)—
- Apr 2017Post IPO$1.2M
#2
Acquired · Pasadena, California · founded 1989 · 427 employees$290.2Mraised▾
Developer of therapeutics to treat multiple diseases. The company develops medicines that treat intractable diseases by silencing the genes that cause them. The company’s pipeline includes ARO-AAT to treat liver diseases, ARO-APOC3 for Hypertriglyceridemia, ARO-ANG3 for Dyslipidemia, and more.
- May 2025Grant (prize money)$305K
- Dec 2017Post IPO$7.2M
- Jan 2017Post IPO$9.7M
- Sep 2016Post IPO$56.5M
#3
Acquired · Solana Beach, California · founded 2009 · 112 employees$468.6Mraised▾
Antibody-based immunotherapeutics for cancer and infectious diseases. it has proprietary platforms that enable fit-for-function bio-therapeutics that optimally interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. Its product pipeline includes INBRX-109 an engineered tetravalent sdAb-based therapeutic candidate to induce tumor selective programmed cell death, and INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 to treat locally advanced or metastatic solid tumors.
- Mar 2025Grant (prize money)$120.1K
- Sep 2023Post IPO$200M
- Feb 2021Grant (prize money)$279.4K
- Apr 2020Conventional Debt$10M
#4
Series A · San Diego, California · founded 2017 · 26 employees$25.4Mraised▾
Producer of cellular agricultural products
- Apr 2025Grant (prize money)$2M
- Sep 2024Series A$6.7M
- May 2024Grant (prize money)$1000K
- Oct 2021Series A$11.5M
#5
Acquired · San Francisco, California · founded 1976 · 13500 employees$72.5Mraised▾
R&D company focused on manufacturing drugs for multiple therapeutic areas. Its products include oncology, immunology, neurology, metabolism, infectious diseases, and ophthalmology drugs. It also provides clinical trial information services.
#6
Funding Raised · San Ramon, California · founded 2004$8.8Mraised▾
Developing peptide therapeutics for neurodegenerative diseases and cardiovascular disease. The company is a clinical-stage biotechnology firm focused on creating innovative treatments for unmet medical needs. They are developing proprietary therapeutics, particularly for neurodegenerative conditions like Alzheimer's disease and cardiovascular diseases linked to diabetes. Their approach involves manipulating the ABCA1 transporter using novel peptides derived from ApoE, aiming to alter cell membrane composition and functionality, especially in brain cells. Their lead compound, CS6253, has shown a favorable safety profile in Phase 1 human studies. The company is also developing Dipep for cardiovascular disease, designed to stabilize plaque and improve glucose tolerance. Their research has been presented at major scientific conferences, and they have peer-reviewed publications. This innovative approach has potential applications in Lewy Body Dementia and traumatic brain injury, offering hope for patients with neurological diseases.
- Apr 2025Grant (prize money)$3M
- Jan 2023Grant (prize money)$3M
- Jun 2019Grant (prize money)$2.9M
#7
Funding Raised · San Diego, California · founded 2001 · 7 employees$12.3Mraised▾
Pioneering small molecule therapies for cancer and inflammatory bowel disease. This company is dedicated to discovering and developing novel therapies for cancer and other serious diseases. They focus on small molecule drugs that target novel members of the nuclear receptor superfamily, a proven class for treating inflammation, oncology, and metabolic disorders. Their pipeline includes first-in-class programs in preclinical and clinical development, with a focus on oncology (including adrenal, head & neck, and squamous cancers) and inflammatory bowel disease (ulcerative colitis and Crohn’s disease). They actively engage with clinical, scientific, investment, and patient communities to advance new therapeutic approaches. Their mission is translational drug discovery and development, leading to first-in-class therapeutics. They are drug hunters committed to bringing innovative treatments to patients in need.
- Dec 2024Grant (prize money)$1.7M
- Sep 2024Grant (prize money)$1.1M
- Jul 2021Grant (prize money)$2M
- Aug 2019Grant (prize money)$1.8M
#8
Series C · San Francisco, California · founded 2017 · 14 employees$15.4Mraised▾
Pin Therapeutics is developing small molecule based therapeutics for the treatment of diseases like cancer, neurodegenerative diseases, cardiovascular diseases, etc. The company has developed a protein degradation technology called PROTAC which utilizes bifunctional compounds to degrade target proteins within the cell. These compounds seize the ubiquitin and/or ubiquitin-like molecule E3 ligase system to degrade target proteins.
- Dec 2024Series C$15.4M
#9
Seed · San Francisco, California · founded 2019 · 5 employees$9.7Mraised▾
Diversified pharmaceutical company
- Jul 2024Grant (prize money)$346.8K
- May 2024Grant (prize money)$324K
- Aug 2023Grant (prize money)$277.1K
- Aug 2023Grant (prize money)$272.1K
#10
Funding Raised · San Francisco, California · founded 2000 · 5 employees$5.9Mraised▾
Developing therapies for fibrosis by modulating glycobiology and innate immunity. The company is focused on translating breakthroughs in fibrosis research into therapies for patients with unmet medical needs. It is a privately-held company focused on modulation of glycobiology and innate immunity to develop treatments for organ fibrosis. The initial target is galectin-3, one of a family of carbohydrate binding proteins. The lead product is a protein inhibitor of galectin-3, for prevention and reversal of fibrosis after myocardial infarction and in heart failure. The company is involved in pharmaceutical and biotech sectors.
- Aug 2024Grant (prize money)$306.9K
- Sep 2018Grant (prize money)$299.9K
- Aug 2016Grant (prize money)$2.2M
- Sep 2013Grant (prize money)$300K
#11
Acquired · San Diego, California · founded 2018 · 5 employees$121Mraised▾
Biopharmaceutical company pioneering targeted protein degradation for innovative medicines, dedicated to developing first-in-class treatments for diseases lacking effective therapeutic approaches. They utilize a proprietary technology platform featuring novel E3 ligands to build the next generation of targeted protein degraders. The mission is to create new drugs for diseases that currently lack effective therapies, expanding the drug design paradigm to drug the "undruggable." They are focused on protein degradation, degrader-antibody conjugates, and novel E3 ligands, leveraging their expertise in UPS and E3s. The company is developing a pipeline of innovative medicines for cancer and other debilitating diseases, pushing the limits of what is possible in medicine.
- May 2023Series B$40M
- Feb 2021Series B$50M
- Apr 2019Series A$16M
- Mar 2018Seed$15M
#12
Series A · Mountain View, California · founded 2018 · 34 employees$30.1Mraised▾
Turn Biotechnologies is reprogramming cells to reverse aging process and treat age-related diseases. The company is engineering aged cells for tissue regeneration and self-renewal, reduction in pro-inflammatory signaling and re-engagement of canonical intracellular nutrient regulation pathways in osteoarthritis tissues.
- Sep 2023Series A$29.1M
- Jul 2022Seed$1M
- Apr 2022Seed—
- Apr 2021Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Diversified Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.